SSRI, Psilocybin, & Esketamine Trials: Control Group Meta-Analysis
Psilocybin’s Antidepressant Efficacy: A Closer Look at Control Group Performance
Table of Contents
The burgeoning enthusiasm for psychedelic-assisted therapies in mental health is undeniable, with psilocybin emerging as a prominent candidate for treating depression.Though, a recent meta-analysis by Hieronymus et al.(2025) casts a critical light on the interpretation of psilocybin’s antidepressant effects, suggesting that observed large effect sizes may be partly attributable to the performance of control groups rather than solely the superiority of the active intervention.
Understanding the Meta-analysis findings
The meta-analysis, which pooled data from trials comparing psilocybin to either placebo or an active comparator, revealed notable differences in control group outcomes across various antidepressant treatments. A key point of discussion was the inclusion of a trial where the control group received escitalopram (a selective serotonin reuptake inhibitor, or SSRI), rather than an inert placebo. Hieronymus et al. justified its inclusion for two primary reasons: first, escitalopram is expected to be at least as effective as a placebo, and second, this specific trial’s control group demonstrated the most substantial pre- to posttreatment enhancement among the four psilocybin studies analyzed. Crucially, excluding this trial did not materially alter the overall results, underscoring the robustness of the findings.
Limitations and Generalizability
It is indeed critically important to acknowledge the limitations of the meta-analysis. The exclusion of studies involving older adults or individuals with acute suicidality, while necessary for methodological rigor in the reviewed trials, inherently limits the generalizability of the findings to these specific populations. A post hoc analysis of three esketamine trials in patients with suicidal ideation highlighted an unusually high control group response (standardized Mean Change, or SMC = 1.87), lending support to the hypothesis that baseline severity and acuity of a condition can influence placebo responsiveness.
Implications for Clinical Adoption and Future Research
The meta-analysis’s findings carry significant implications for stakeholders considering the widespread clinical or formulary adoption of psilocybin. While psilocybin continues to show promise in alleviating depressive symptoms, the research suggests that its large observed effect sizes might be partially driven by less favorable outcomes in control groups. Specifically, control participants in psilocybin trials exhibited notably lower response rates (19%) and smaller symptom improvements (SMC = 0.50) when contrasted with control groups in SSRI (SMC = 1.00) and esketamine (SMC = 1.12) trials. This disparity points towards a potential heightened vulnerability to expectancy bias and functional unblinding within psilocybin trials.
For regulatory bodies and payers, these insights underscore the imperative for more rigorous trial designs. Future research should prioritize methodologies that effectively minimize unblinding and adeptly manage patient expectations to ensure that efficacy signals are not overstated. Moreover, the current limited number and inherent heterogeneity of psilocybin trials necessitate further examination. This includes studies employing diverse and representative patient populations to build a more comprehensive understanding of psilocybin’s therapeutic potential. until such robust evidence emerges, claims regarding psilocybin’s broad effectiveness in treating depression warrant careful consideration of the trial context and the performance of control groups.
References
- Heal DJ, smith SL, Belouin SJ, Henningfield JE. Psychedelics: threshold of a therapeutic revolution. Neuropharmacology. 2023;236:109610. doi:10.1016/j.neuropharm.2023.109610
- Hieronymus F, López E, Werin sjögren H, Lundberg J. Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis. JAMA Netw Open. 2025; 8 (7): E2524119. DOI: 10.1001/JamanetWorkOPen.2025.24119
- Carhart-Harris R, Gribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402-1411. doi:10.1056/NEJMoa2032994